SE0300988D0 - New use - Google Patents

New use

Info

Publication number
SE0300988D0
SE0300988D0 SE0300988A SE0300988A SE0300988D0 SE 0300988 D0 SE0300988 D0 SE 0300988D0 SE 0300988 A SE0300988 A SE 0300988A SE 0300988 A SE0300988 A SE 0300988A SE 0300988 D0 SE0300988 D0 SE 0300988D0
Authority
SE
Sweden
Prior art keywords
new use
angiotensin
prevention
treatment
combination
Prior art date
Application number
SE0300988A
Other languages
English (en)
Swedish (sv)
Inventor
Anders Ljunggren
Anders Svensson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0300988A priority Critical patent/SE0300988D0/xx
Publication of SE0300988D0 publication Critical patent/SE0300988D0/xx
Priority to MXPA05010660A priority patent/MXPA05010660A/es
Priority to KR1020057017718A priority patent/KR20050114671A/ko
Priority to BRPI0408979-0A priority patent/BRPI0408979A/pt
Priority to PCT/SE2004/000505 priority patent/WO2004087136A1/en
Priority to NZ542640A priority patent/NZ542640A/en
Priority to EP04724927A priority patent/EP1613309A1/en
Priority to US10/550,760 priority patent/US20060194856A1/en
Priority to CNA2004800093941A priority patent/CN1771033A/zh
Priority to AU2004226517A priority patent/AU2004226517B2/en
Priority to JP2006507997A priority patent/JP2006522115A/ja
Priority to CA002520960A priority patent/CA2520960A1/en
Priority to IL170706A priority patent/IL170706A0/en
Priority to NO20054370A priority patent/NO20054370L/no
Priority to ZA200507945A priority patent/ZA200507945B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE0300988A 2003-04-03 2003-04-03 New use SE0300988D0 (sv)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SE0300988A SE0300988D0 (sv) 2003-04-03 2003-04-03 New use
CA002520960A CA2520960A1 (en) 2003-04-03 2004-03-31 Use of atii antagonist for the treatment or prevention of metabolic syndrome
EP04724927A EP1613309A1 (en) 2003-04-03 2004-03-31 Use of atii antagonist for the treatment or prevention of metabolic syndrome
CNA2004800093941A CN1771033A (zh) 2003-04-03 2004-03-31 应用atii拮抗剂治疗或预防代谢综合征
BRPI0408979-0A BRPI0408979A (pt) 2003-04-03 2004-03-31 uso de um antagonista e receptor de tipo 1 da angiotensina ii sozinho ou em combinação com uma substáncia anti-hipertensiva metabolicamente neutra, e, método para o tratamento e/ou prevenção de sìndrome metabólica
PCT/SE2004/000505 WO2004087136A1 (en) 2003-04-03 2004-03-31 Use of atii antagonist for the treatment or prevention of metabolic syndrome
NZ542640A NZ542640A (en) 2003-04-03 2004-03-31 Use of angiontensin II antagonists including losartan, candesartan, cilexetil, irbesartan and candesartan for the treatment or prevention of metabolic syndrome or Syndrome X
MXPA05010660A MXPA05010660A (es) 2003-04-03 2004-03-31 Uso de anti-antagonistas para el tratamiento o prevencion de sindrome metabolico.
US10/550,760 US20060194856A1 (en) 2003-04-03 2004-03-31 Use of atii antagonist for the treatment or prevention of metabolic syndrome
KR1020057017718A KR20050114671A (ko) 2003-04-03 2004-03-31 대사 증후군의 치료 또는 예방을 위한 ａｔｉｉ 길항제의용도
AU2004226517A AU2004226517B2 (en) 2003-04-03 2004-03-31 Use of ATII antagonist for the treatment or prevention of metabolic syndrome
JP2006507997A JP2006522115A (ja) 2003-04-03 2004-03-31 代謝症候群の処置または予防のためａｔｉｉアンタゴニストの使用
IL170706A IL170706A0 (en) 2003-04-03 2005-09-06 Use of atii antagonist for the treatment or prevention of metabolic syndrome
NO20054370A NO20054370L (no) 2003-04-03 2005-09-21 Anvendelse av ATII-antagonist for behandling og forhindring av metabolsk syndrom
ZA200507945A ZA200507945B (en) 2003-04-03 2005-09-30 Use of ATII antagonist for the treatment or prevention of metabolic syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0300988A SE0300988D0 (sv) 2003-04-03 2003-04-03 New use

Publications (1)

Publication Number Publication Date
SE0300988D0 true SE0300988D0 (sv) 2003-04-03

Family

ID=20290927

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0300988A SE0300988D0 (sv) 2003-04-03 2003-04-03 New use

Country Status (15)

Country Link
US (1) US20060194856A1 (ko)
EP (1) EP1613309A1 (ko)
JP (1) JP2006522115A (ko)
KR (1) KR20050114671A (ko)
CN (1) CN1771033A (ko)
AU (1) AU2004226517B2 (ko)
BR (1) BRPI0408979A (ko)
CA (1) CA2520960A1 (ko)
IL (1) IL170706A0 (ko)
MX (1) MXPA05010660A (ko)
NO (1) NO20054370L (ko)
NZ (1) NZ542640A (ko)
SE (1) SE0300988D0 (ko)
WO (1) WO2004087136A1 (ko)
ZA (1) ZA200507945B (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008067378A2 (en) * 2006-11-28 2008-06-05 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted phenyltetrazoles
JP2015509969A (ja) * 2012-03-16 2015-04-02 グルソックス・バイオテック・アーベー Ｎｏｘ４阻害活性を示すチオフェン−ベースの化合物および療法におけるその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5266583A (en) * 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
GB9406573D0 (en) * 1994-03-31 1994-05-25 Merck Sharp & Dohme Medicaments
DE4439947A1 (de) * 1994-11-09 1996-05-15 Boehringer Mannheim Gmbh 2,2-Dichloralkancarbonsäuren, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
EP1870098A3 (en) * 1998-07-10 2010-07-07 Novartis Ag Combined use of valsartan and calcium channel blockers for therapeutic purposes
SK14612002A3 (sk) * 2000-04-12 2003-05-02 Novartis Ag Farmaceutická kompozícia obsahujúca inhibítor aldosterónsyntázy prípadne v kombinácii s antagonistom AT1-receptora a jej použitie
US20030187038A1 (en) * 2000-08-25 2003-10-02 Yoshimi Imura Fibrinogen-lowering agents
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20030092736A1 (en) * 2001-05-30 2003-05-15 Cheng Peter T. Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
WO2004060399A1 (ja) * 2002-12-27 2004-07-22 Takeda Pharmaceutical Company Limited 体重増加抑制剤

Also Published As

Publication number Publication date
JP2006522115A (ja) 2006-09-28
KR20050114671A (ko) 2005-12-06
NO20054370L (no) 2005-10-31
EP1613309A1 (en) 2006-01-11
NZ542640A (en) 2008-06-30
MXPA05010660A (es) 2005-12-12
AU2004226517A1 (en) 2004-10-14
CN1771033A (zh) 2006-05-10
ZA200507945B (en) 2007-04-25
CA2520960A1 (en) 2004-10-14
US20060194856A1 (en) 2006-08-31
WO2004087136A1 (en) 2004-10-14
NO20054370D0 (no) 2005-09-21
IL170706A0 (en) 2009-02-11
BRPI0408979A (pt) 2006-04-04
AU2004226517B2 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
MX2009001327A (es) Compuestos de indol.
ATE423114T1 (de) Aminocyclopropancarbonsäureamidderivate als bradykininantagonisten
DE50306232D1 (de) Ampholytisches copolymer und dessen verwendung
RS51106B (sr) Derivati prolina i njihova upotreba kao inhibitora dipeptidil peptidaze iv
ID26984A (id) Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
SG146657A1 (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2006137934A3 (en) Purposeful movement of human migratory cells away from an agent source
JO2356B1 (en) N-by-phenyl derivatives (methyl substituted) amino cycloalkan carboxamide
ZA200500966B (en) Biphasic composition induced by polydextrose and sucrose
TW200833684A (en) 5,6-ring annulated indole derivatives and methods of use thereof
ATE371645T1 (de) Naphthalinderivate, die sich an den ep4?rezeptor binden
EA200100937A1 (ru) Способы и композиции, использующие (-)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов
WO2005074598A3 (en) Nitroxyl progenitor compounds and methods of use
UA85574C2 (uk) Ендопаразитоцидний засіб для місцевого застосування
DK1824493T3 (da) Oral suspension, der omfatter meloxicam
HK1103073A1 (en) Substituted diaza-spiro-[5.5-undecane derivatives and their use as neurokinin antagonists
EA200100936A1 (ru) Способы и композиции, использующие (+)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов
WO2006020680A3 (en) Heterocyclic compounds as pharmaceutical agents
RS50611B (sr) "BEZILAT SO 7 - (2- (4- (3 – TRIFLUOROMETIL - FENIL) -1, 2, 3, 6" TETRAHIDRO - PIRID-1- ILI)ETIL)IZOHINOLlNA, NJENO DOBIJANJE I NJENA TERAPEUTSKA PRIMENA
DE60303441D1 (en) N-biphenylmethylaminocycloalkancarboxamid-derivative
ATE399776T1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
RS54185B1 (en) USE OF 24-ORDER
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
DE602005007858D1 (de) Medizinische seife
WO2005041878A3 (en) Compositions and methods for increasing hdl and hdl-2b levels